AWARENESS OF MEDICAL APPLICATIONS OF MODAFINIL THERAPY AMONG DENTAL STUDENTS
DOI:
https://doi.org/10.61841/s0vbkf92Keywords:
Awareness, Modafinil therapy, dental studentsAbstract
Modafinil had initially evolved by a French neurophysiologist Professor Michel Jouvet. Modafinil started with the late 1970s creation of a progression of benzhydryl sulfinyl mixes, including adrafinil that was used in the management of narcolepsy in 1986. Modafinil is fundamentally utilized for its antisomnic function. The aim of the survey is for assessing the awareness of medical applications of Modafinil therapy amongst dental students. A cross-sectional study was done with a self-administered questionnaire with 10 questions circulated among 100 dental students. The questionnaire assessed the awareness about Modafinil therapy in medical applications, their medicinal uses, antisomnic activity, mechanism of action and side effects. The responses were recorded and analysed.94 % of the respondents were not aware of medical uses of Modafinil therapy .83 % were not aware of antisomnic activity therapy.90 % were not aware of the mechanism of action of Modafinil therapy .85% were not aware of side effects of Modafinil therapy. The awareness about the use of Modafinil therapy in medical applications is very less among dental students. Increased awareness programs and sensitization and continuing dental education programs along with greater importance to the curricular modifications should be incorporated to improve the awareness levels.
Downloads
References
1. Andrade, C., Kisely, S., Monteiro, I., & Rao, S. (2015). Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. Journal of Psychiatric Research, 60, 14–21.
2. Ballas, C. A., Kim, D., Baldassano, C. F., & Hoeh, N. (2002). Modafinil: past, present and future. In Expert Review of Neurotherapeutics (Vol. 2, Issue 4, pp. 449–457). https://doi.org/10.1586/14737175.2.4.449
3. Camacho, A., & Stein, M. B. (2002). Modafinil for Social Phobia and Amphetamine Dependence. In American Journal of Psychiatry (Vol. 159, Issue 11, p. 1947 – a). https://doi.org/10.1176/appi.ajp.159.11.1947-a
4. Connolly, J. J., Glessner, J. T., Kao, C., Elia, J., & Hakonarson, H. (2015). Attention-Deficit Hyperactivity Disorder and Pharmacotherapy—Past, Present, and Future. In Therapeutic Innovation & Regulatory Science (Vol. 49, Issue 5, pp. 632–642). https://doi.org/10.1177/2168479015599811
5. Eckart, W. U. (2006). Man, Medicine, and the State: The Human Body as an Object of Government Sponsored Medical Research in the 20th Century. Franz Steiner Verlag.
6. Elliott, L., & Swick, T. (2015). Treatment paradigms for cataplexy in narcolepsy: past, present, and future. In Nature and Science of Sleep (p. 159). https://doi.org/10.2147/nss.s92140
7. Jha, A., Weintraub, A., Allshouse, A., Morey, C., Cusick, C., Kittelson, J., Harrison-Felix, C., Whiteneck, G., & Gerber, D. (2008). A Randomized Trial of Modafinil for the Treatment of Fatigue and Excessive Daytime Sleepiness in Individuals with Chronic Traumatic Brain Injury. In Journal of Head Trauma Rehabilitation (Vol. 23, Issue 1, pp. 52–63). https://doi.org/10.1097/01.htr.0000308721.77911.ea
8. Lavault, S., Dauvilliers, Y., Drouot, X., Leu-Semenescu, S., Golmard, J.-L., Lecendreux, M., Franco, P., & Arnulf, I. (2011). Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Medicine, 12(6), 550–556.
9. Mankad, M. V., Beyer, J. L., Weiner, R. D., & Krystal, A. (2010). Clinical Manual of Electroconvulsive Therapy. American Psychiatric Pub.
10. Mehlman, M. J. (2009). The Price of Perfection: Individualism and Society in the Era of Biomedical Enhancement. JHU Press.
11. Portela, M. A., Rubiales, Á. S., & Centeno, C. (2011). The use of psychostimulants in cancer patients. In Current Opinion in Supportive and Palliative Care (Vol. 5, Issue 2, pp. 164–168). https://doi.org/10.1097/spc.0b013e3283462ff3
12. Rush, C. R., Kelly, T. H., Hays, L. R., Baker, R. W., & Wooten, A. F. (2002). Acute behavioral and physiological effects of modafinil in drug abusers. In Behavioural Pharmacology (Vol. 13, Issue 2, pp. 105–115). https://doi.org/10.1097/00008877-200203000-00002
13. Taylor, F. B., & Russo, J. (2000). Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. Journal of Child and Adolescent Psychopharmacology, 10(4), 311–320.
14. Wisor, J. (2013). Modafinil as a Catecholaminergic Agent: Empirical Evidence and Unanswered Questions. In Frontiers in Neurology (Vol. 4). https://doi.org/10.3389/fneur.2013.00139
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
